InflaRx N.V. (IFRX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

InflaRx N.V. (IFRX) closed at USD 1.48 on 2026-10-14, a change of -2 % over the past year, with a market capitalization of USD 212.21M.

InflaRx N.V. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

InflaRx N.V. key figures

Previous close

USD 1.48 (2026-10-14)

1-year change

-2 %

Market cap

USD 212.21M

Enterprise value

USD 54.53M

P/E ratio (trailing)

-2.48

P/E ratio (forward)

-3.71

EPS (trailing)

-0.58

EPS (forward)

-0.39

PEG ratio

n/a

Price to book

1.29

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

24.81

Employees

65

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About InflaRx N.V.

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for InflaRx N.V. and compare it with other stocks.